What is Brief History of Coherus Biosciences Company?

Coherus Biosciences Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the history of Coherus BioSciences?

Coherus BioSciences, established in 2010 as BioGenerics, Inc., has evolved significantly. Initially focused on biosimilar therapeutics, the company has strategically shifted its emphasis towards innovative oncology treatments.

This transformation culminated in the divestiture of its UDENYCA franchise in April 2025, marking a decisive move towards becoming a specialized oncology entity.

The company's journey from a biosimilar developer to a commercial-stage oncology innovator highlights its adaptability and commitment to advancing cancer therapies. This strategic pivot aims to address unmet needs in cancer treatment, building on its foundation of developing high-quality therapeutics. For a deeper understanding of its market position, consider a Coherus Biosciences Porter's Five Forces Analysis.

Coherus BioSciences, initially established as BioGenerics, Inc. in September 2010, officially adopted its current name in April 2012. The company was co-founded by Denny Lanfear, who has consistently led as Chairman, President, and Chief Executive Officer since its inception. The founding team brought together a wealth of experience from the pharmaceutical and biotechnology sectors, recognized for their contributions to the early development of biotherapeutics in the United States.

Coherus Biosciences Founding Story

The genesis of Coherus BioSciences stemmed from a clear market need: the demand for more affordable alternatives to high-cost branded biologic drugs. The company's foundational business model focused on the research, development, and commercialization of biosimilar products, with the overarching goal of improving patient access to critical therapies.

• Co-founded by Denny Lanfear in September 2010.
• Initial name was BioGenerics, Inc., changed to Coherus BioSciences, Inc. in April 2012.
• Founding team comprised experienced biotech pioneers.
• Mission to provide cost-effective biologic alternatives.

The early vision for Coherus BioSciences was to address the growing healthcare cost burden by developing biosimilar versions of established biologic medicines. This strategic focus aimed to provide patients and healthcare systems with more economical treatment options. The company's initial efforts were directed towards advancing its product candidates through crucial clinical development stages, including Phase 1 and Phase 3 trials. This period of early development was critical in establishing the company's scientific and clinical foundation. The Brief History of Coherus Biosciences details these formative years.

Securing adequate funding was paramount for the company's ambitious development plans. By 2014, Coherus BioSciences had successfully raised over $220 million through a combination of equity financing and non-dilutive revenue streams such as licensing fees and milestone payments. A significant milestone in its early financial history was the closing of a $55 million Series C Preferred stock financing round on May 19, 2014. This round saw participation from prominent new investors, including KKR & Co. L.P., Venrock, and RA Capital Management, alongside existing investors. The economic climate of the time, characterized by escalating healthcare expenditures and the impending patent expirations of several blockbuster biologic drugs, created a highly favorable environment for biosimilar development companies like Coherus BioSciences.

Coherus Biosciences SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early years of Coherus Biosciences were marked by a strategic focus on building a robust portfolio of biosimilar products. This phase saw the company concentrate on developing high-quality, cost-effective alternatives to established biologic therapies, aiming to make advanced treatments more accessible.

Early Product Development and Launches

Coherus BioSciences initially concentrated on developing a strong pipeline of biosimilars. A significant early success was the launch of UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, which quickly became a key revenue generator for the company. The development of CIMERLI (ranibizumab-eqrn), a biosimilar to Lucentis, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira, further solidified its market presence, with YUSIMRY launching in the U.S. in 2023.

Market Entry and Pricing Strategy

These product launches demonstrated Coherus's ability to bring cost-effective biosimilar options to market, typically priced at approximately 15-30% lower than their originator counterparts. This strategy aimed to drive adoption and contribute to overall healthcare cost savings.

Operational Footprint and Investment in R&D

The company's operations were centered at its headquarters in Redwood City, California, supported by additional facilities including a lab in Camarillo, CA. The intensive research and development required for biosimilar creation led to significant investment, with Coherus allocating $78.3 million to R&D for its biosimilar candidates in 2024, alongside $150 million dedicated to clinical trials. By the fourth quarter of 2023, Coherus had established a specialized sales force of 87 direct representatives focused on oncology and immunology.

Financial Growth and Strategic Partnerships

Beyond initial seed funding, Coherus secured a $55 million Series C round in May 2014, contributing to over $220 million in total funding by that year. The market generally responded positively to biosimilars due to their potential for cost reduction, with Coherus contributing to an estimated $127 million in annual healthcare savings through competitive pricing by 2024. To broaden its market reach, Coherus engaged in strategic partnerships for global commercialization across Europe, Asia, and Latin America, and collaborated with manufacturing and supply chain partners. Understanding the nuances of these market entries is crucial, as detailed in the Marketing Strategy of Coherus Biosciences.

Coherus Biosciences PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Coherus BioSciences has navigated a dynamic biopharmaceutical sector, marking key achievements and undergoing significant strategic shifts. The company's early success was anchored by the development and commercialization of UDENYCA, a biosimilar that became a crucial revenue stream. A pivotal transformation occurred with the company's accelerated focus on innovative immuno-oncology, significantly boosted by the 2021 in-licensing of toripalimab (LOQTORZI) from Junshi Biosciences. This next-generation PD-1 inhibitor received FDA approval for nasopharyngeal carcinoma (NPC) and was launched in January 2024. The company's commitment to oncology was further demonstrated through the acquisition of Surface Oncology in September 2023, adding two promising clinical-stage assets to its pipeline.

Coherus BioSciences has introduced significant innovations, notably the development of LOQTORZI, a PD-1 inhibitor that received a Preferred designation from the NCCN for nasopharyngeal carcinoma in both first-line and second-line settings in November 2024. The company also advanced its pipeline through the acquisition of Surface Oncology, bringing in novel assets targeting advanced solid tumors.

LOQTORZI: Next-Generation PD-1 Inhibitor

LOQTORZI's FDA approval for nasopharyngeal carcinoma and subsequent NCCN Preferred designation highlight its therapeutic significance. This innovation represents a key advancement in the company's immuno-oncology strategy.

Pipeline Expansion via Acquisition

The acquisition of Surface Oncology bolstered the company's oncology pipeline with differentiated assets like casdozokitug (anti-IL-27) and CHS-114 (anti-CCR8). These additions are aimed at targeting advanced solid tumors, further diversifying the company's therapeutic focus.

UDENYCA Commercialization

The successful development and commercialization of UDENYCA, a biosimilar to Neulasta, established a foundational revenue stream for the company. This achievement demonstrated the company's capability in bringing biosimilar products to market.

Coherus BioSciences has faced persistent challenges, including consistent net losses since its inception and intense market competition, which necessitated a significant strategic realignment. The company's decision to divest its UDENYCA franchise and reduce its headcount by approximately 30% reflects a strategic response to these financial and competitive pressures, aiming to streamline operations and concentrate resources.

Financial Losses and Competition

The company has historically reported net losses, a common challenge in the biopharmaceutical industry, particularly for companies investing heavily in research and development. Intense competition within the biosimilar and oncology markets further compounded these financial pressures.

Strategic Divestiture and Restructuring

The divestiture of the UDENYCA franchise, valued at up to $558.4 million, and a subsequent workforce reduction of about 30% were critical steps to address financial challenges. These actions were taken to improve financial flexibility and focus resources on the high-growth oncology segment, a move that also impacted its Competitors Landscape of Coherus Biosciences.

Focusing Resources for Impact

The strategic repositioning and rebranding to Coherus Oncology underscore a critical lesson learned: the importance of concentrating resources in high-innovation areas. This focus aims to maximize impact and drive growth within the competitive immuno-oncology landscape.

Coherus Biosciences Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The Coherus Biosciences history is one of strategic transformation, evolving from its inception to become a focused oncology enterprise. This journey involved key acquisitions and divestitures, reshaping its identity and market focus.

Maximizing LOQTORZI Potential

The company is focused on accelerating LOQTORZI's commercial growth. Projections indicate $150 million to $200 million in annual revenue from the NPC indication alone over the next three years.

Pipeline Advancement

Strategic initiatives include expanding LOQTORZI's indications through combination therapies with internal assets like casdozokitug and CHS-114. Key clinical data readouts for CHS-114 and casdozokitug are anticipated in the first half of 2026.

Strategic Partnerships

The company plans to seek partnerships for the ex-U.S. commercialization of its pipeline assets. This aligns with its refined vision of becoming a leader in cancer care.

Market Outlook

Analysts maintain a 'Buy' consensus rating for Coherus Biosciences (CHRS), with a median price target of $6.00 as of April 29, 2025. This reflects a potential upside and positive market sentiment.

Coherus Biosciences Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔